WOCKPHARMANSE26 February 2024

Wockhardt Limited has informed the Exchange about Investor Presentation

Wockhardt Limited

WOCK/SEC/SE/2023-24/072

26th February, 2024

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001

National Stock Exchange of India Limited Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

Scrip Code: 532300

NSE Symbol – WOCKPHARMA

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith a copy of the Investor Presentation for your records.

The said Investor Presentation has also been uploaded on the Company’s website and can be accessed through the following link:

https://www.wockhardt.com/investors/analyst-investors/presentation/

You are requested to kindly take it on record.

Thanking you, Yours Sincerely,

Rashmi Mamtura Company Secretary

Encl.: A/a.

Investor presentation

2024

Disclaimer

This presentation and the accompanying slides (the “Presentation") contain selected information about the activities of Wockhardt Limited ("Company") and its subsidiaries (together, the “Group") as at the date of this presentation. It does not purport to present a comprehensive overview of the Group or contain all the information necessary to evaluate an investment in the Company.

The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or, the recommendation or solicitation of an offer or invitation to purchase any securities of the Company in India, the United States or any other jurisdiction. This presentation should not, nor should anything contained in it, form the basis of, or be relied upon in any connection with any contract or commitment whatsoever.

This presentation is not intended to be a “prospectus” or “ or “draft offer document” or “offer document” or “final offer document” or “offer letter” or “offering memorandum”(as defined or referred to, as the case may be, under the Companies Act, 2013 and the rules notified thereunder or any other applicable law, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended). It is clarified that this Presentation is not intended to be a document or advertisement offering for subscription or sale of any securities or inviting offers or invitations to offer or solicitation to offer from the public (including any section thereof) or any class of investors. This document has not been and will not be reviewed or approved by a regulatory authority in India or elsewhere or by any stock exchange in India or elsewhere. The distribution of this presentation in certain jurisdictions may be restricted by law, and the recipients into whose possession the presentation come should inform themselves about and observe such restrictions. Any decision to purchase securities in the context of an offering of securities (if any) should be made solely on the basis of information contained in the offering documentation published in relation to such offering. You will be solely responsible for your own assessment of the market and the market position of the Group, and you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

This Presentation and the information contained herein, is strictly confidential and is intended only for the exclusive use of the recipients thereof, subject to the provisions stated herein, and may not be disclosed, reproduced, published, transmitted, summarized, distributed or furnished, in or whole or in part, or passed on directly or indirectly to any other person or persons whether within or outside your organization or firm, or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. Any printed form of this Presentation must be returned to us immediately at the conclusion of this Presentation. This Presentation is being communicated to selected persons who have professional experience in matters relating to investments for information purposes only and does not constitute a recommendation regarding any securities of the Group. Other persons should not rely or act upon this Presentation or any of its contents.

The Group may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes. This presentation may contain forward looking statements that involve risks and uncertainties. Forward looking statements are based on certain beliefs, plans and expectations of the Group about the future. Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy, future outlook and growth prospects, and future developments in businesses and/or competitive and regulatory environment No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that any objectives specified herein will be achieved. Actual future performance, outcomes and results may differ materially from those expressed in forward looking

statements as a result of a number of risks, uncertainties and assumptions. Although the Group believes that such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Representative examples of factors that could affect the accuracy of forward looking statements include (without limitation) the condition of and changes in India’s political and economic status, government policies, applicable laws, the industries relevant to the Group in India, and international and domestic events having a bearing on the Group’s business, and such other factors beyond the Group’s control. You are cautioned not to place undue reliance on these forward looking statements, which are based on current views of the Group’s management on future events.

If the Company should at any time make an offering of securities, any decision to invest in any such offer to subscribe for or acquire securities of the Company must be based wholly on the information contained in the offer document or offering circular, placement document, and/or any international offering memorandum (including the risk factors mentioned therein) issued or to be issued by the Company in connection with any such offer and not on the contents herein. Information contained in this presentation is qualified in its entirety by reference to an offering document for any potential transaction if it proceeds. Any potential transaction could be made available to the recipient of this document in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to the recipient, herein or otherwise.

No representation or warranty express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Group, its directors, officers or employees or its affiliates, its advisors or representatives, or any such person's officers or employees accepts any liability (in negligence or otherwise) whatsoever arising directly or indirectly from the use of this presentation.

The contents of this presentation have not been independently verified and this presentation has been prepared by the Group, solely for informational purposes Neither the delivery of this presentation nor any further discussions with any of the recipients shall, under any circumstance, create any implication that there has been no change in the affairs of the Group. This presentation is a summary only and it is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the financial position or prospects of the Group.

Certain data contained in this presentation was obtained from various external data sources, and none of the Group, its advisers or representatives has verified this data with independent sources Accordingly, the Group, its advisers and representatives make no representation as to the fairness, accuracy, correctness, authenticity or completeness of that data, and this data involves risks and uncertainties and is subject to change based on various factors. The information contained in this presentation is not to be taken as any recommendation made by the Group or any other person to enter into any agreement with regard to any investment. You will be solely responsible for your own assessment of the market and the market position of the Group, and you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

By participating in this Presentation, attendees agree to be bound by the foregoing limitations Any failure to comply with these restrictions may constitute a violation of applicable securities law

Snapshot of Wockhardt

Net sales Revenues (9M FY24)

INR 2,129 Cr.

12 manufacturing facilities across world

EBITDA (9M FY24)

INR 173 Cr.

Net Debt: Equity Ratio (as on September 30, 2023)

International Business (9M FY24)

0.27x*

78%

e r u t c u r t s a r f n I

2 R&D centres one each in India, UK

~ 315 scientists with 55 PhD’s; Drug Discovery team ~ 125 associates

3,262 patents filed; 837 patents granted

Pharma Generics

Biotechnology (focus on Diabetes)

Vaccines

New Chemical Entity (focus on novel Antibiotics)

* Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances

Global footprint

Global operations

Capability across different segments

► Branded

► OTC

► Hospitals

► Antibiotics Drug Discovery

► Biotechnology

► Pharma Generics

► Solids

► Injectables

► Liquids

► Nasal sprays

► Biotechnology

► Complex technologies

Direct operations

Through Partners

United Kingdom

Emerging Markets

India

Ireland

USA

► Retail & Hospital

segments

► Vaccine CMO

► Presence in

Southeast Asia, East Asia, Africa, the CIS region and Latin America countries

► Pain, Diabetes,

Nephrology, CNS portfolio

► >750** field force

► Branded Generic &

OTC

► Retail pharmacies,

wholesalers & hospitals.

► Restructuring -

facility shutdown

► Shift to third party manufacturing

► Defocusing Pharma R&D

36%

21%

22%

*9M FY 23-24 (Others: 9%) **as on 31st December 2023

% sales revenue contribution for 9M FY23 -24

Financial Highlights

Net Sales Revenues INR Cr.

EBITDA INR Cr.

307

328

3,239

489

2,840 130

2,693

7% growth

2,129

1,983

2,710

2,750

2,667

1,959

2,124

71 98

80% growth

173 5

168

143 19

124

96 17

FY21

FY22

FY23

9M FY23

9M FY24

FY21

FY22

FY23

9M FY23

9M FY24

FY Figures Excl. Vaccine

FY Figures for Vaccine

9M Figures Excl. Vaccine

9M Figures Vaccine

-27

-21

Reduction in External Term Loans

Reduction in external term loan* (INR Cr.)

2,054

1,262

825

555

438

Mar-20

Mar-21

Mar-22

Mar-23

Sep-23

*Excluding promoter debt & preference capital

Net Debt : Equity @ 0.27*

Total Equity INR Cr.

Total Borrowings* INR Cr.

Total Borrowings* Reduction by > INR 600 Cr.

3,759

4,202

3,662

3,432

FY21

FY22

FY23

6M FY24

1,568

FY21

882

FY22

975

933

FY23

6M FY24

Cash & cash equivalents and other Bank balances INR Cr.

Net Debt-Equity Ratio *

292

FY21

406

FY22

124

FY23

6M FY24

0.42

FY21

0.21

FY22

0.27

FY23

0.27

6M FY24

* Excluding promoter debt & preference capital & net of Cash & cash equivalents and other Bank balances

Additional Short-term and Mid-term growth drivers

3 years growth drivers

5 years growth drivers

Diabetes Biosimilars for India + Emerging markets – Human Insulin & Glargine

Novel drug discovery - WCK 5222, Nafithromycin, Emrok

Novel drug discovery – WCK 5222, Nafithromycin, WCK 6777

Diabetes Biosimilars for India + Emerging markets – New Insulin Analogs and GLP1 Agonists

Vaccines

New Chemical Entity (Antibiotics)

Anti-microbial resistance (AMR) could cause 10 million deaths by 2050 ‘Tackling Drug-Resistant infections globally’ chaired by JIM O’NEILL- Former Minister, UK Govt. & Former Chairman Goldman Sachs’

A failure to address the

problem of antibiotic

Deaths attributable to antimicrobial resistance every year compared to other major causes of death

AMR in 2050 10,000,000

resistance could result in

Tetanus 60,000

Cholera 100,000-120,000

Measles 130,000

AMR 700,000

10 Million deaths

globally by 2050,

costing £ 66 trillion

http://amr-review.org/

Road traffic accidents 1,200,000

Diarrheal disease 1,400,000

Diabetes 1,500,000

Cancer 1,400,000

Wockhardt’s Novel Antibiotics

~25 years

Focused commitment to Novel Antibiotics research leading to end-to-end Discovery & Development capabilities

Programs granted QIDP* status by US FDA denoting unmet needs; faster trials, quicker approvals by US FDA

* Qualified Infectious Disease Product (QIDP) status granted by US FDA eligible for fast track development process and priority review. QIDP status also grants five

year extension to the market exclusivity in the United States

Novel Antibiotics pipeline encompassing all the Resistant Organisms

Gram Negative Portfolio

Gram Positive Portfolio

WCK 5222

WCK 4282

WCK 6777

Emrok / Emrok O

Nafithromycin

Status

Global Phase III ongoing

Meropenem resistant pathogen study (India)

Phase III ready

Phase I In collaboration with NIH (US)

Launched in India; Filed in Emerging Markets

Phase III completion in India

Potential Indication

cUTI, HABP / VABP (Global) + Carbapenem Resistant infections (India)

cUTI HABP / VABP

cUTI

ABSSSI

CABP / RTI

Target Market

Global

Emerging Market

Positioning

Destination therapy for difficult-to-treat Gram-ve Klebsiella, Acinetobacter and Pseudomonas

Empiric-use; Carbapenem- sparing Gram-ve

Out-patient therapy for MDR Gram -ve

MDR Gram+ve Anti-MRSA

Macrolide-resistant Respiratory Pathogens, Quinolone-Sparing

HABP: Hospital Acquired Bacterial Pneumonia; VABP: Ventilator Acquired Bacterial Pneumonia cUTI : Complicated urinary tract infections; CABP: Community-acquired bacterial pneumonia ; RTI: Respiratory Tract Infection; ABSSSI: Acute bacterial skin and skin structure infections; MDR: Multidrug resistance ; Gram –ve: Gram Negative ; Gram +ve: Gram Positive

WCK 5222 Development Status (Brand name: ZaynichTM *)

WCK 5222 (Cephalosporin + β-lactam enhancer) – Destination therapy for XDR Gram Negative Acinetobacter & Pseudomonas

Pre-clinical

Phase I

Phase II1

Completed

Global Phase III (on-going)

Regulatory filings

Global Launch

► Phase I studies completed

Unmet Need

► Pulmonary PK, renal impairment and cardiovascular

safety studies completed

► Phase III clinical study based on US FDA accepted

development path

► Global Phase III cUTI study ongoing: >50% patient

recruitment completed

► Meropenem-resistant clinical study set for first patient

recruitment for early launch in India

► Patents secured in key global markets; strong IP

protection

1. Phase II waiver *- Trademark filed in India

► Carbapenem resistant Pseudomonas and Acinetobacter (20-95%)

infections are desperately treated with efficacy and safety- compromised colistin/polymyxin/tigecycline.

► WCK 5222 would provide a safer and consistently efficacious

therapy for such life-threatening infections.

Compassionate Use

100% clinical and microbiological success thus far in 15 patients with extremely difficult to treat infections, where all the available therapies failed

WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (1/2)

Patients with Life threatening infections

Failed treatment

Pathogen and Drug Resistance

Complicated intra-abdominal infection induced-sepsis Febrile neutropenia, Thalassemia major, failed bone marrow transplant, bloodstream infection Acute T cell lymphoblastic leukaemia, pneumonia, bloodstream infection Lung infection leading to empyema, lung part excision with chronic pulmonary TB

Bilateral sequential lung transplant, osteomyelitis,

Osteomyelitis + maxillary sinusitis & pneumonia

Polymyxin-B (2 weeks)

XDR

Pseudomonas aeruginosa

PIP/TAZ, Meropenem, CAZ/AVI & Aztreonam

XDR

Escherichia coli

Polymyxin-B & Meropenem therapy

XDR

Pseudomonas aeruginosa

CAZ/AVI & Aztreonam (3 weeks) as well as Colistin (1 week) Multiple rounds of Tigecycline, CAZ/AVI, Meropenem Colistin, Fosfomycin (6 weeks), Meropenem (2 weeks)

Pan- drug resistant

Pseudomonas aeruginosa

MDR

Serratia marcescens

Pseudomonas Resistant to>>

Osteomyelitis (bone infection of chest wall)

Colistin therapy

MDR

Bronchopleural fistula, Ventilated Pneumonia

Polymyxin-B and ceftazidime/avibactam therapy

MDR

Pseudomonas & Acinetobacter

DRUG RESISTANCE

WCK 5222

1 g u r D

2 g u r D

3 g u r D

4 g u r D

Treat- ment Duration

y c a c i f f E

y t e f a S

Outcomes

10 days ✓ ✓ • Complete

20 days ✓ ✓

resolution of infection

32 days ✓ ✓

22 days ✓ ✓

• Patient’s Clinical condition improved

22 days ✓ ✓

70 days ✓ ✓

49 days ✓ ✓

10 days ✓ ✓

• Well tolerated

• WCK 5222 was well tolerated even at adult doses in paediatric patients

Drug 1: Carbapenems ; Drug 2. Ceftazidime/ Avibactam (CAZ/AVI) Drug 3.Imipenem/ Relebactam; Drug 4.Ceftolozane/ Tazobactam

R: Resistant; S: Susceptible

100% clinical and microbiological success

WCK 5222: Compassionate use results in 15 patients (incl. 2 paediatric) (2/2)

DRUG RESISTANCE

WCK 5222

Patients with Life threatening infections

Failed treatment

Pathogen and Drug Resistance

Liver Transplant, HTN, Hypothroidism, Hospital- acquired Pneumonia on Ventilation Endovascular Infection Post Arterial graft

Colistin and Doripenem therapy

MDR

Pseudomonas Resistant

Urosepsis & septic shock, on ventilation & inotropic support

Colistin, Meropenem, PIP/TAZ

Multiple rounds of CAZ/AVI+Aztreonam

MDR

Pseudomonas Resistant

Pseudomonas aeruginosa

Pancytopenia, abscess in liver , consistent fever spikes

Colistin, CAZ/AVI+Aztreonam, Meropenem

MDR

Klebsiella pneumoniae

Severe septic shock, fever spikes, lung infection and required inotropic support

Bone and Joint Infection: Left malignant otitis externa w/ lateral skull base osteomyelitis

Complicated Intra Abdominal Infection with Spleen abscess (Recurrent abscess/sepsis)

Fosfomycin, Colistin and Levofloxacin

Pan-drug resistant

Pseudomonas aeruginosa

No other antibiotics tried based on past experience of treating physician

MDR

Pseudomonas aeruginosa

with Fosfomycin

MDR

Pseudomonas aeruginosa

1 g u r D

2 g u r D

3 g u r D

4 g u r D

Treat- ment Duration

y c a c i f f E

y t e f a S

12 Days ✓ ✓

14 Days ✓ ✓

30 Days ✓ ✓

Isolate not available for WCK 5222 susceptibility testing. Patient treated with WCK 5222 empirically at the discretion of clinician

30 Days ✓ ✓

5 Days ✓ ✓

42 Days ✓ ✓

28 Days ✓ ✓

Drug 1: Carbapenems ; Drug 2. Ceftazidime/ Avibactam (CAZ/AVI) Drug 3.Imipenem/ Relebactam; Drug 4.Ceftolozane/ Tazobactam

R: Resistant; S: Susceptible

100% clinical and microbiological success

Outcomes

• Complete resolution of infection

• Patient’s Clinical condition improved

• Well tolerated

• WCK 5222 was well tolerated even at adult doses in paediatric patients

Pathogens inflicting infections and associated indications while treating 15 patients with WCK 5222 in compassionate setting

Complete clinical as well as microbiological cure attained in all patients

Indication wise split for patients treated under compassionate use

Pathogen

Bone & Joint Infection**

22-70 days

15 patients

Complicated Intra- Abdominal Infection

28-30 days

Blood Stream infection

5-20 days

Treatment duration

cUTI with Pseudomon as Sepsis

30 days

Pneumonia (HABP, VABP, empyema)*

10-32 days

* 1/5 patients also had cIAI, 1/5 patients also had cSSSTI & BSI ** 1/4 patients also had pneumonia

Pseudomonas aeruginosa

Acinetobacter baumannii + Pseudomonas aeruginosa

Escherichia coli

Serratia marcescens

Klebsiella pneumoniae

15 Patients treated

Treatment duration

11a

5 to 70 days

10 days

20 days

22 days

30 days

b. c. d. e.

9/11 patients had Colistin / Polymyxin failure; 3/11 patients had CAZ/AVI & Aztreonam failure; 1/11 patients had Fosfomycin IV failure Patient had Polymyxin & CAZ/AVI failure Patient had CAZ/AVI + Aztreonam failure Patient had CAZ/AVI & Tigecycline failure Patient had CAZ/AVI + Aztreonam & Colistin failure

Polymyxin-B / Colistin therapy had already failed in 10 out of these 15 patients; WCK 5222 dose adjustment was required in only 4 out of these 10 patients

WCK 5222 differentiation

Strictly confidential. Not for further circulation

Activity against resistant infection

Best comparable Pipeline Drugs

Best available Approved Drugs

Organism/ Resistance Mech.

WCK 52221

Product 1

Product 2

Product 3

Product 4

Product 5

Product 6

Product 7

Product 8

Product 9

K. pneumoniae (ESβL)

K. pneumoniae (KPC)

K. pneumoniae (MβL)

E. coli (PBP3 insert+ESBL/Class C)

E. coli (MβL± PBP3 Insert)

Enterobacter (AmpC)

Proteus (ESβL, Class C)

P. aeruginosa (AmpC + oprD +Efflux)

P. aeruginosa (Oxa, oprD + Efflux)

P. aeruginosa (MβL)

A. baumannii (CHDL, OXA)

S. maltophilia MDR/XDR

1. WCK 5222: Wockhardt’s combination of Cefepime (Cephalosporin) with Zidebactam (β-lactam enhancer); Product 1.Cefepime/taniborbactam ; Product 2.Aztreonam/avibactam ; Product 3. Cefiderocol ; Product 4.Imipenem/relebactam ;Product 5.Meropenem/vaborbactam ; Product 6.Plazomicin ; Product 7.Ceftazidime/avibactam ; Product 8.Sulbactam/durlobactam ;Product 9.Imipenem or meropenem

Most Isolates Susceptible

Variable Susceptibility

Most Isolates Resistant

Top 6 Super bugs inflicting global mortality in 2019 - more than 3.5 Millions deaths

Number of deaths associated with Anti-Microbial Resistance*

829,000

642,000

748,000

596,000

423,000

334,000

Acinetobacter

Escherichia Coli

Klebsiella

Pseudomonas

Staphylococcus

Pneumococcus

WCK 5222 is designed to address all the major Super Bugs including Pseudomonas, Klebsiella, E. coli and Acinetobacter

* Lancet. 2022 Feb 12;399(10325):629-655

Nafithromycin (Brandname: MiqnafTM *): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) and Upper Respiratory tract infections(RTI)

Increasing resistance and incomplete coverage for current treatment options: • •

Azithromycin resistance in S. Pneumonia of ~65% in India** Lack of atypical pathogen coverage by Amoxicillin/Clavulanic acid

Nafithromycin has broad spectrum (covers entire range of gram +ve, gram -ve & atypicals) enabling monotherapy; effective against Azithromycin resistant strains / multi-drug resistance bacteria with 100% coverage based on high lung concentrations

Successfully completed phase III study with 96.77 % of cure rate in CABP and other respiratory infections, with safety profile commensurate with community usage

Lung penetration profile - Human lung exposure 8 times higher than Azithromycin

Ultra short duration therapy (3 day) with Once Daily dosing treatment regimen for improved patient compliance

Phase I and Phase II conducted by reputed global CRO’s in US & EU. Phase III completed in India and commercialization expected in short term

*- Trademark filed in India *-AMR Surveillance Network, Indian Council of Medical Research, 2022. Susceptibility and resistance to Azithromycin is determined by testing Erythromycin as per CLSI

EMROK & EMROK O: Multi-spectrum anti-MRSA Drug

Emrok / Emrok O®: Launched in India and filed in select Emerging markets

New Age Antibiotic : Benzoquinolizine sub-class

Multi-spectrum activity: Safe Oral and IV antibiotic with coverage of MDR Gram Positive pathogens including MRSA, Gram Negative, Anaerobic & Atypicals

EMROK & EMROK O - Only rapidly bactericidal agent available for MRSA infections with excellent penetration in Biofilms associated with Bone and Joint infections, Prosthetic Joint infections and Catheter-associated infections

Biotechnology

Strategic pillars of Diabetes Biosimilars

Focus on Diabetes Injectable portfolio

Vertically integrated

Human Insulin, Insulin Glargine commercialized

Research and Development

Yeast, mammalian and bacterial platform

Robust Pipeline of Insulin Analogs and GLP1 Agonists under development

Drug substance manufacturing

4 facilities

Drug product manufacturing

2 facilities

Patented delivery device

Disposable Pen, Reusable Pen

Business Organization

Direct presence in 10 Emerging markets (incl. India)

Competitive advantage by providing end-to-end solutions in Diabetes Biosimilars

Integrated capabilities

R&D

Manufacturing

Regulatory

Devices

Focus on Insulin

Pilot to large scale

Registrations in 40+

Customised precision

analogues, GLP1

capabilities for API &

countries

patented delivery

agonists

formulations

devices

Pipeline of Insulin Analogs including Insulin Aspart & Lispro

Patented delivery devices (pen)

Vials

Cartridges

Enhanced competitive posture to help penetrate markets

Development status of Insulin analogues and GLP-1 agonist

Aspart R

Aspart 30/70

Lispro R

Lispro 25/75

Liraglutide

Process development

Process Scale Up

Drug substance validation batches

Drug product validation batches

PK/PD study

✓

Analytical similarity

Ongoing

E.Coli host cell as platform technology for all above products ✓ Completed * To be further scaled up

✓

✓*

✓

✓*

Planned

✓

Ongoing

Planned

Diabetes Biosimilars for Emerging markets - Competitive scenario

Limited competition

6-7 players

Registered in emerging markets

> 40 markets

Competitive scenario

Manufacturing infrastructure ready

Integrated end to end capabilities

API + Formulation

Development to marketing

Barriers to entry- development time, dedicated manufacturing

Under registration in 7 countries

Low cost manufacturing

Own patented device

Focus on Human Insulin & Insulin Glargine

> US$ 1.5 Billion market

Potential for deeper market penetration

Pipeline: Aspart R & Aspart Mix

~ US$ 1.1 Billion market

PK/PD development stage

Vaccine: Supply & Collaboration agreement with Serum at UK Facility

• Profit sharing of 51:49 with Serum Life Sciences Limited in favor of Wockhardt

• 15 years arrangement

• Reserved capacity of 150 million doses per annum

Abbreviation

ABSSSI: Acute bacterial skin and skin structure infections; AmpC : AmpC beta-lactamases AMR: Antimicrobial resistance API: Active Pharmaceutical Ingredient CIS: Commonwealth of Independent States CABP: Community-acquired bacterial pneumonia CHDL: Carbapenem-hydrolyzing class D β-lactamases CLSI: Clinical & Laboratory Standards Institute CMO : Contract Manufacturing Organization CNS: Central Nervous System CRO : Clinical research Organisation cUTI : Complicated urinary tract infections EBITDA: Earnings before Interest, Tax, Depreciation and Amortization ESBL : Extended Spectrum Beta-Lactamase GLP1: Glucagon-like peptide 1 GMP: Good Manufacturing Practice HABP: Hospital Acquired Bacterial Pneumonia KPC : Klebsiella pneumoniae carbapenemase

MBL : Metallo-β-lactamases MDR: Multidrug resistance MENA: Middle East and North Africa MRSA : Methicillin-resistant Staphylococcus aureus NIH (US): National Institutes of Health (NIH), OD: Once a day OTC : Over the counter PBP3: Penicillin-binding protein 3 PK/PD study : Pharmacokinetic-Pharmacodynamic R&D: Research and Development RTI: Respiratory Tract Infection; USFDA : United States Food and Drug Administration. VABP: Ventilator Acquired Hospital Pneumonia WCK 4282: Cefepime/Tazobactam WCK 5222: Cefepime/Zidebactam WCK 6777: Ertapenem/Zidebactam XDR : Extensively Drug Resistant

Thank You

← All Transcripts WOCKPHARMA Stock Page →

Wockhardt Limited has informed the Exchange about Investor Presentation

Market Movers